Parenteral Nutrition (PN)

(Total Parenteral Nutrition)

Full Review: Nov 2026 ByKris M. Mogensen, MS, RD-AP, Department of Nutrition, Brigham and Women's Hospital | Malcolm K. Robinson, MD, Harvard Medical School | Peer reviewed byGlenn D. Braunstein, MD, Cedars-Sinai Medical Center
Last updated: Nov 2026
v883492
View Patient Education

Parenteral nutrition (PN) is an essential therapeutic modality across a range of age groups (neonates, children, and adults), indications, and care settings. PN is by definition nutrition that is given via non-enteral routes (ie, in practice, via IV). PN may be infused through a peripheral or central venous access device, depending on the osmolarity of the solution (1).

Peripheral PN may be infused through a peripheral venous access device. The osmolarity of the solution should be ≤ 900 mOsm/L (1). A solution with a higher osmolarity may cause thrombophlebitis.

Central PN requires a central venous access device for safe infusion because solutions formulated for central PN have an osmolarity > 900 mOsm/L (1).

Because of its complexity, appropriate use of PN should maximize its clinical benefit while minimizing risk of adverse events. PN should not be used routinely in patients with an intact gastrointestinal (GI) tract. Compared with enteral nutrition, PN has the following disadvantages:

  • More complications

  • Poorer preservation of the structure and function of the GI tract

  • Higher cost

General reference

  1. 1. Boullata JI, Gilbert K, Sacks G, et al. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enteral Nutr. 2014;38(3):334-377. doi:10.1177/0148607114521833

Indications for Parenteral Nutrition

PN may be the only feasible option for patients who do not have a functioning GI tract or who have disorders requiring complete bowel rest, such as the following (1):

Indications reference

  1. 1. Worthington P, Balint J, Bechtold M, et al. When Is Parenteral Nutrition Appropriate?. JPEN J Parenter Enteral Nutr. 2017;41(3):324-377. doi:10.1177/0148607117695251

Nutritional Requirements and Formula Content

PN requires that patients receive water, usually 25 to 40 mL/body weight (kg)/day. Less water is needed for patients requiring fluid restriction, energy, amino acids, lipids, vitamins, and minerals (see table ).

Children who need PN may have different fluid requirements and need more energy (up to 120 kcal/kg/day) and amino acids (up to 2.5 or 3.5 g/kg/day).

Table
Table

Solutions for Parenteral Nutrition

Standardized, commercially available PN solutions are available for institutions that do not have the resources to make individualized solutions. Individualized PN solutions may be prepared using sterile techniques. For individualized PN solutions, electrolytes may be adjusted based on laboratory results and changes in clinical status.

Standard vitamin and trace element preparations are also available to add to PN to meet micronutrient requirements. The stability of the PN solution depends on many factors. To prevent electrolyte precipitation, additional electrolytes should not be added to standardized PN solutions. Because stability can be reduced by modifications to PN solutions, modifications (eg, adding electrolytes or other substances) should be reviewed by an experienced pharmacist.

PN macronutrient composition varies depending on solution type:

  • Peripheral PN: Lower amino acid and dextrose concentrations to keep the osmolarity low, with most calories from fat

  • Central PN: Higher amino acid and dextrose concentrations to provide more energy in less volume

Amino acid dose is based on the patient's calculated protein requirements.

The American Society for Parenteral and Enteral Nutrition has published recommendations for appropriate dosing of lipid emulsions (1, 2). The availability of mixed-oil lipid emulsions has changed the approach to lipid dosing in PN, intending to balance provision of nutrients with potential adverse effects. Soybean oil is rich in omega-6 polyunsaturated fatty acids, which have been associated with proinflammatory and immunosuppressive effects. Thus, traditional lipid emulsions of 100% soybean oil should be restricted to < 1 g/kg/day in patients who are critically ill but can be dosed up to 1 g/kg/day in patients who are stable. Mixed-oil lipid emulsions include combinations of soybean oil, olive oil, medium-chain triglycerides (MCTs), and fish oil, which have lower omega-6 polyunsaturated fatty acids and allow for higher total fat delivery. For adults (both stable and critically ill), 1 to 1.5 g/kg/day of the lipid emulsion blend of olive oil and soybean oil can be given, whereas 1 to 2 g/kg/day of the lipid emulsion blend of soybean oil, MCTs, olive oil, and fish oil can be given. In the United States, 100% fish oil lipid emulsion is not used in adults, but it may be used as a therapy for children with intestinal-failure–associated liver disease in jurisdictions where it is available. Additional dosing considerations (eg, medication additives; calcium, phosphorus, and magnesium content) to ensure solution stability should be reviewed by an experienced pharmacist.

If the total energy provided by amino acids and lipids is less than the total energy required, dextrose monohydrate is generally used to make up the shortfall. However, the maximum amount of carbohydrate is typically 4 to 7 mg/kg/minute and < 4 mg/kg/minute in patients who are critically ill; administration of carbohydrate at greater than this rate can lead to hyperglycemia (3). Also, overfeeding energy can lead to excessive carbon dioxide production and metabolic dysfunction-associated steatotic liver disease (MASLD); overfeeding is often attributed to excessive carbohydrate delivery. Using mixed-oil lipid emulsions allows lower carbohydrate delivery and may help reduce complications of excessive carbohydrate delivery.

PN solution volumes, types, and concentrations vary depending on patient factors, such as concomitant disorders and age:

  • For patients with heart, liver, or kidney failure: Limited volume (liquid) intake

  • For patients with diabetes: Mixed-oil lipid emulsion, providing the upper end of the recommended dosing range to allow for reduction of dextrose delivery

  • For neonates: Lower dextrose concentrations (17 to 18%)

Solutions references

  1. 1. Mirtallo JM, Ayers P, Boullata J, et al. ASPEN Lipid Injectable Emulsion Safety Recommendations, Part 1: Background and Adult Considerations. Nutr Clin Pract. 2020;35(5):769-782. doi:10.1002/ncp.10496

  2. 2. Cober MP, Gura KM, Mirtallo JM, et al. ASPEN lipid injectable emulsion safety recommendations part 2: Neonate and pediatric considerations. Nutr Clin Pract. 2021;36(6):1106-1125. doi:10.1002/ncp.10778

  3. 3. Lesser MNR, Lesser LI. Nutrition Support Therapy. Am Fam Physician. 2021;104(6):580-588.

Administration of Parenteral Nutrition

As with any central venous catheter, strict sterile technique must be used during insertion and maintenance of the catheter. The PN lumen of the central line should not be used for any other purpose. External tubing should be changed every 24 hours with the first PN solution bag of the day. The American Society for Parenteral and Enteral Nutrition recommends using a 1.2-micron in-line filter when PN is administered to reduce exposure to particulate matter (1). Dressings should be kept sterile and are usually changed every 48 hours using strict sterile techniques.

Parenteral Nutrition

Parenteral nutrition is delivered through a central venous catheter. The catheter is inserted into a large vein, such as the subclavian vein.

Credit: DNA Illustrations/SCIENCE PHOTO LIBRARY

PN may be administered at home, particularly in patients with chronic medical conditions requiring ongoing, long-term nutritional support (2). If PN is given outside the hospital, patients and their care partners must be taught appropriate line care, PN administration, and identification of complications, including symptoms of infection. Qualified home nursing must be arranged.

The PN solution is typically initiated with 100 to 150 g dextrose on the first day. The initial PN volume may be restricted on the first day, so additional IV fluids may be required to meet fluid needs.

PN should be advanced based on electrolyte and clinical stability. Special considerations apply in the event of hyperglycemia (3). If a patient is hyperglycemic, blood glucose concentrations should be monitored and regular insulin should be provided. No other insulin type is compatible with PN solutions. The target blood glucose level for patients receiving PN is < 180 mg/dL (10 mmol/L) while the solution is infusing. Regular insulin may be added directly to the PN solution as needed. A typical starting dose is 1 unit of regular insulin/10 g dextrose; patients with pre-existing diabetes may require additional insulin (4). Collaboration with an endocrinologist can help optimize management of blood glucose levels.

Administration references

  1. 1. Worthington P, Gura KM, Kraft MD, et al. Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper. Nutr Clin Pract. 2021;36(1):29-39. doi:10.1002/ncp.10587

  2. 2. Durfee SM, Adams SC, Arthur E, et al. A.S.P.E.N. Standards for Nutrition Support: Home and Alternate Site Care. Nutr Clin Pract. 2014;29(4):542-555. doi:10.1177/0884533614539017

  3. 3. McMahon MM, Nystrom E, Braunschweig C, et al. A.S.P.E.N. clinical guidelines: nutrition support of adult patients with hyperglycemia. JPEN J Parenter Enteral Nutr. 2013;37(1):23-36. doi:10.1177/0148607112452001

  4. 4. American Diabetes Association Professional Practice Committee for Diabetes. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S339-S355. doi:10.2337/dc26-S016

Monitoring of Parenteral Nutrition

An interdisciplinary nutrition team composed of a physician, dietitian, pharmacist, and nurse, if available, should monitor patients (1).

A complete blood count should be obtained. Weight, electrolytes, magnesium, phosphorus, blood urea nitrogen, and creatinine should be monitored often (eg, daily for inpatients, weekly for outpatients). Plasma glucose should be monitored every 6 hours until patients and their glucose levels become stable. Liver tests should be monitored at least weekly, but more frequent monitoring may be required if test results are abnormal. Triglyceride levels should be monitored at least twice/week in inpatients receiving lipid emulsions. Fluid intake and output should also be monitored continuously.

When patients become stable, blood tests can be performed less often. Blood tests should not be performed while PN is being infused.

Full nutritional assessment (including BMI calculation, anthropometric measurements, and body composition analysis) should be repeated as often as dictated by a patient's clinical status. Adjustments to the nutritional assessment may be needed more frequently in patients who are critically ill and less frequently in outpatients who are stable and receiving PN.

Clinical Calculators

Monitoring reference

  1. 1. Ukleja A, Gilbert K, Mogensen KM, et al. Standards for Nutrition Support: Adult Hospitalized Patients. Nutr Clin Pract. 2018;33(6):906-920. doi:10.1002/ncp.10204

Complications of Parenteral Nutrition

Complications of PN are common and mainly involve catheter-related infection, metabolic abnormalities (eg, glucose, electrolyte, fluid, lipid abnormalities), and organ-related disorders (hepatic, gallbladder, and metabolic bone disease). Most complications are preventable or reversible with careful monitoring and adjustment of the PN formulation. Approximately 3% of patients with a central venous catheter for PN may experience severe complications related to central venous access (1).

Catheter-related complications

Catheter-related sepsis rates have decreased since the introduction of CDC guidelines that emphasize sterile techniques for catheter insertion and skin care around the insertion site (2). The increasing use of dedicated teams of physicians and nurses who specialize in various procedures including catheter insertion also has contributed to a decrease in catheter-related infection (eg, central-line associated bloodstream infection [CLABSI]) rates.

Infectious complications associated with PN have been reduced by changes in PN management such as avoiding overfeeding, maintaining optimal blood glucose concentrations, and using mixed-oil lipid emulsions.

Metabolic complications

Glucose abnormalities are common. Hyperglycemia can be avoided by monitoring plasma glucose often, adjusting the insulin dose in the PN solution, and giving subcutaneous insulin as needed. Hypoglycemia can be precipitated by suddenly stopping constant concentrated dextrose infusions. Treatment depends on the degree of hypoglycemia. Short-term hypoglycemia may be reversed with 50% dextrose IV; more prolonged hypoglycemia may require infusion of 5 or 10% dextrose for 24 hours before resuming PN via the central venous catheter.

Adverse reactions to lipid emulsions (eg, dyspnea, cutaneous allergic reactions, nausea, headache, back pain, sweating, dizziness) are uncommon but may occur early, particularly if lipids are given at > 0.11 g/kg/hour. Temporary hyperlipidemia may occur, particularly in patients with kidney or liver failure; treatment is usually not required. Delayed adverse reactions to lipid emulsions include hepatomegaly, mild elevation of liver enzymes, splenomegaly, thrombocytopenia, leukopenia, and, especially in premature infants with respiratory distress syndrome, pulmonary function abnormalities. Temporarily or permanently slowing or stopping lipid emulsion infusion may prevent or minimize these adverse reactions.

Abnormalities of serum electrolytes and minerals should be corrected by modifying subsequent infusions or, if correction is urgently required, by beginning appropriate peripheral vein infusions. Vitamin and mineral deficiencies are rare when solutions are given correctly. Elevated blood urea nitrogen may reflect dehydration, which can be corrected by giving free water as 5% dextrose via a peripheral vein or increasing the volume of water provided in the PN.

Volume overload (suggested by > 1 kg/day weight gain) may occur when patients have high daily energy requirements and thus require large fluid volumes. A pharmacist with expertise managing PN should review the PN solution to determine whether the volume of the solution can be reduced.

Organ-related complications

Hepatic complications include liver dysfunction, painful hepatomegaly, and hyperammonemia. These complications can develop at any age but are most common among infants, particularly premature ones (whose livers are immature); hepatomegaly in infants presents as an irritability and fussiness with right-sided abdominal swelling.

Liver dysfunction may be transient, evidenced by increased transaminases, bilirubin, and alkaline phosphatase; it commonly occurs when PN is started. Delayed or persistent elevations may result from excess amino acids. Pathogenesis is unknown, but cholestasis and inflammation may contribute. Progressive fibrosis may occasionally develop. Fish oil lipid emulsions may be beneficial; in children, 100% fish oil lipid emulsion is a rescue therapy for this complication.

If infants develop any hepatic complication, limiting amino acids to 1.0 g/kg/day may be necessary.

Gallbladder complications include cholelithiasis, gallbladder sludge, and cholecystitis. These complications can be caused or worsened by prolonged gallbladder stasis. Stimulating contraction by providing about 20 to 30% of calories as fat and stopping glucose infusion several hours a day is helpful. Oral or enteral intake also helps. Treatment with metronidazole, ursodeoxycholic acid, phenobarbital, or cholecystokinin helps some patients with cholestasis.

Metabolic bone disease, or bone demineralization (osteoporosis or osteomalacia), develops in some patients given PN for > 3 months. The mechanism is unknown. Advanced disease can cause severe periarticular, lower-extremity, and back pain.

Complications references

  1. 1. Teja B, Bosch NA, Diep C, et al. Complication Rates of Central Venous Catheters: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024;184(5):474-482. doi:10.1001/jamainternmed.2023.8232

  2. 2. Centers for Disease Control and Prevention (CDC): Guidelines for the Prevention of Intravascular Catheter-Related Infections (2011). Accessed August 14, 2026.

Key Points

  • Consider parenteral nutrition for patients who do not have a functioning gastrointestinal tract or who have disorders requiring complete bowel rest.

  • Calculate requirements for water, energy, amino acids, lipids, vitamins, and minerals.

  • Choose a solution based on patient age and organ function status; different solutions are required for neonates and for patients who have compromised heart, kidney, or liver function.

  • Use a central venous catheter, with strict sterile technique for insertion and maintenance.

  • Monitor patients closely for complications (eg, related to central venous access; abnormal glucose, electrolyte, mineral levels; hepatic or gallbladder effects; reactions to lipid emulsions; and volume overload or dehydration).

Drug Information for the Topic

quizzes_lightbulb_red
Test your KnowledgeTake a Quiz!
iOS ANDROID
iOS ANDROID
iOS ANDROID